Details : TNP-2092 is a multi-targeting drug conjugate, exerting its antibacterial activity by inhibiting three essential targets RNA Polymerase, DNA Gyrase and Topoisomerase IV.
Product Name : TNP-2092
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 23, 2021
Lead Product(s) : TNP-2092
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TenNor Therapeutics Received FDA Orphan Drug Designation
Details : TenNor has completed a Phase II clinical trial for TNP-2092 in the United States for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and received positive results.
Product Name : TNP-2092
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 20, 2020
Lead Product(s) : TNP-2092
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
